The 2 most recent market catalysts affecting $MXCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate
MaxCyte's Q2 earnings report showed a smaller loss per share than anticipated and sales that exceeded analyst consensus. This indicates better-than-expected operational performance…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 65
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
MaxCyte announced a technology license partnership with Genentech, a subsidiary of Roche, granting Genentech access to MaxCyte's ExPERT GTx platform for cell therapy development. T…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.